TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Renapharma AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
35,635
|
30,205
|
30,159 |
| Financial expenses |
0
|
77
|
32 |
| Earnings before taxes |
5,347
|
6,603
|
7,374 |
| EBITDA |
7,867
|
7,171
|
7,899 |
| Total assets |
41,324
|
44,263
|
37,137 |
| Current assets |
19,299
|
21,686
|
19,441 |
| Current liabilities |
4,160
|
9,664
|
7,708 |
| Equity capital |
31,208
|
26,497
|
19,895 |
| - share capital |
100
|
100
|
100 |
| Employees (average) |
4
|
4
|
4 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
75.5%
|
59.9%
|
53.6% |
| Turnover per employee |
8,909
|
7,551
|
7,540 |
| Profit as a percentage of turnover |
15.0%
|
21.9%
|
24.5% |
| Return on assets (ROA) |
12.9%
|
15.1%
|
19.9% |
| Current ratio |
463.9%
|
224.4%
|
252.2% |
| Return on equity (ROE) |
17.1%
|
24.9%
|
37.1% |
| Change turnover |
5,430
|
46
|
7,056 |
| Change turnover % |
18%
|
0%
|
31% |
| Chg. No. of employees |
0
|
0
|
1 |
| Chg. No. of employees % |
0%
|
0%
|
33% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.